Menu Close

Author: WorkCompAcademy

Anti-Inflammatory Medications May Increase Long Term Disability Risk

A new study, published Wednesday in the journal Science Translational Medicine claims that the treatments often used to soothe pain in the lower back might cause it to last longer.

According to the study authors, chronic pain inflicts huge societal costs, in terms of management, loss of work productivity, and effects on quality of life. And chronic low back pain (LBP) is the most frequently reported chronic pain condition. LBP ranks the highest of all chronic conditions in terms of years lived with disability, with its prevalence and burden increasing with age.

Current treatments for LBP often target the immune system and include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and corticosteroids, although all of these drug classes are minimally effective at best.

The transition from acute to chronic pain is critically important but not well understood. Despite advances in the understanding of social, psychological, and genetic factors, as well as brain processes associated with chronic LBP, scientists understand very little of the molecular mechanisms underlying the acute-to-chronic pain transition that might lead to more efficacious analgesic strategies.

Therefore the researchers investigated the pathophysiological mechanisms underlying the transition from acute to chronic low back pain (LBP) and performed transcriptome-wide analysis in peripheral immune cells of 98 participants with acute LBP, followed for 3 months.

Transcriptomic changes were compared between patients whose LBP was resolved at 3 months with those whose LBP persisted.

Clinical data showed that the use of anti-inflammatory drugs was associated with increased risk of persistent pain, suggesting that anti-inflammatory treatments might have negative effects on pain duration. Analysis of pain trajectories of human subjects reporting acute back pain in the UK Biobank identified elevated risk of pain persistence for subjects taking NSAIDs.

Thus, despite analgesic efficacy at early time points, the management of acute inflammation may be counterproductive for long-term outcomes of LBP sufferers.

Researchers then replicated their findings using a prospective cohort of similar design. The replication cohort comprised subjects with another musculoskeletal pain condition, temporomandibular disorders (TMD). Although the pathophysiology of TMD is likely not identical to LBP, they hypothesized that the active contribution of the immune system in the transition to chronic pain could be shared.

The authors say that these conclusions may have a substantial impact on medical treatment of the most common presenting complaints to health care professionals. Specifically, the data suggest that the long-term effects of anti-inflammatory drugs should be further investigated in the treatment of acute LBP and likely other pain conditions.

Flu Vaccine May Also Provide Some COVID-19 Protection

The influenza vaccine is protective against the influenza virus, reducing the number of cases and deaths that occur with this seasonal pathogen. Flu shots are a high priority for older adults and healthcare workers (HCWs) at a greater risk of infection and complications.

Earlier research suggests a link between SARS-CoV-2 infection/adverse COVID-19 outcomes and prior influenza vaccination. There was a need to make sure that this was not because flu shots are more likely to be taken by the health-conscious, who are also more compliant with protective health behaviors against COVID-19. This is called the healthy user effect and is a potential source of bias in such studies.

The current study, which appears on the medRxiv* preprint server, was conducted among health care workers at Hamad Medical Corporation, the principal provider of public healthcare services in Qatar and the nationally designated entity for COVID-19-related healthcare needs.

It included over 30,000 healthcare workers vaccinated against influenza during the period between September 17, 2020, and December 31, 2020, when the annual flu shots are usually given. Significantly, this was before the rollout of COVID-19 vaccines.

The vaccinated participants had a median age of 36 years, while a control group had a slightly lower median age of 35. All participants received the quadrivalent Influvac Tetra vaccine (Abbott). Cases and controls were in a ratio of 1:5.

The results showed that the flu shots reduced the risk of SARS-CoV-2 over the next two weeks by 30%. Conversely, they reduced the risk of severe or fatal COVID-19 by 90%. Of nearly 130 individuals who tested positive for SARS-CoV-2 by PCR after taking the flu shot, one developed severe COVID-19 (requiring hospitalization), and none progressed to critical or fatal disease.

In contrast, among nearly 400 unvaccinated patients who tested positive, there were 17 severe and 2 critical cases, though no deaths occurred.

It must be noted however, that the study included small numbers of severe cases. Nonetheless, the evidence supports the reported effectiveness of the influenza vaccine against both infection with and COVID-19 disease as a result of SARS-CoV-2.

The protection mechanism is as yet unexplained. More importantly, the study is not generalizable because it includes mostly young, healthy HCWs. However, this negates the healthy user bias. Overall, therefore, “The findings support benefits for influenza vaccination that extend beyond protection against influenza infection and severe disease.”

May 9, 2022 – News Podcast


Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories:
Workers Seek Order Prohibiting WCAB “Grant and Study” Recon Orders. Walmart Avoids $504K in Photo Shoot Model Late Pay Penalties. Temecula Physician to Serve 8 Years for $12M Medicare Fraud. Ruling in Kaiser Fraud Case Illustrates Sophisticated Upcoding Strategies. Biden Signs Law Limiting Employer Arbitration Mandates. Travelers Report Says 35% of Injuries Occur During First Year on Job. Physicians Combine Virtual Reality and Robotics For Safer Surgeries. California Opioid Addiction Physicians Struggle with Sublocade Solution. UCSD Smartphone App Screens for Neurological Disease. New Safety Standards Helps Organizations Prevent Workplace Injuries.

NCCI State of the Line Report Shows WC is “Strong and Healthy”

The National Council on Compensation Insurance (NCCI) released its performance metrics for the US workers compensation system for 2021. NCCI’s annual State of the Line presentation provides an exclusive review of trends, cost drivers, and significant developments shaping the workers compensation industry.

Private carrier plus state fund net written premium increased about 1% to $43 billion in 2021 (private carrier premium alone was $38B). Private carriers again posted a profitable Calendar Year 2021 combined ratio of 87. It is the fifth consecutive year with a combined ratio below 90 for the workers compensation insurance market and the eighth consecutive year of underwriting profitability.

“The strength and resilience of the workers compensation system is a point of pride for all stakeholders,” said Bill Donnell, President and CEO of NCCI. “As the workforce and workplaces are changing, the industry must step up again to fulfill its noble responsibility: helping injured workers.”

“Strong employment and significant wage growth are fueling workers compensation payroll increases,” NCCI Chief Actuary Donna Glenn added. “We have a remarkably strong and healthy system right now.”

Additional key insights in NCCI’s State of the Line Report include:

– – The workers compensation line is strong and healthy.
– – WC results continue to reflect a strong financial position.
– – Lost-time claim frequency data suggests the long-term decline has continued, despite a rise in frequency in 2021. Since 2019, frequency declined slightly.
– – The 2021 changes in indemnity and medical claim severity are expected to be flat.
– – The number of COVID-19 claims declined in 2021 relative to the prior year.
– – Workers compensation reserves grew to $16 billion redundant as of year-end 2021.
– – The system saw its eighth consecutive year of underwriting profitability with a calendar year combined ratio of 87, outperforming other property-casualty lines.
– – The 2018 to 2021 loss ratios have been the lowest observed in at least 30 years
– – Net written premiums rose about 1% in 2021.
– – Between 2020 and 2021, countrywide private carrier direct written premium increased 1.9%.
– – State funds saw a larger increase in premium compared with private carriers.
– – Lost-time claim frequency data suggests the long-term decline continues, despite a rise in frequency in 2021. Since 2019, frequency has declined slightly.
– – There is no change expected in medical and indemnity claims severity in 2021.
– – There are potential challenges ahead as medical costs could experience inflationary pressure.
– – Workers compensation reserves are robust. Reserves grew to $16 billion redundant as of year-end 2021.
– -Total property and casualty net written premium for private carriers increased by approximately 9% to more than $700 billion in 2021.

Glenn issued the State of the Line Report at NCCI’s Annual Insights Symposium on May 10 in Orlando, FL.  The State of the Line Report and State of the Line Guide are available online.

San Mateo Hemp Farm Owner Sentenced for Lack of Comp Coverage

The San Mateo County District Attorney’s Office announced that David Wayne Jenkins was sentenced to 364 days in custody, after a plea of no contest to charges related to his failure to pay farm workers at the hemp farm he was operating in Half Moon Bay.

Jenkins also pled no contest to charges that he failed to transmit taxes withheld from his employees’ wages and failed to maintain a workers’ compensation insurance policy.

He started a hemp farm in Half Moon Bay in December of 2019, and employed between 30 and 40 employees throughout 2020 under the business name Castle Management.

He paid employees every two weeks and withheld taxes from employees’ paychecks between April 2020 and Nov. 2020, but despite being warned to do so by his payroll service, he never registered Castle Management with the Employment Development Department, nor were any of the withheld taxes transferred to the Employment Development Department.

Because his business was failing financially, the defendant stopped paying his employees altogether at the beginning of December 2020.

At each pay period he provided employees with a variety of excuses for why they hadn’t been paid, and continued working the employees without pay until January 28, 2021, when investigators with the Labor Commissioner’s Office issued a stop work order.

After an extensive investigation conducted by the District Attorney’s Bureau of Investigation, the Labor Commissioner’s Office and Employment Development Department, Jenkins was charged in a felony complaint for theft of labor, tax evasion, and failure to maintain workers’ compensation insurance.

As part of an April plea agreement, Jenkins pled no contest to two counts of grand theft of labor as felonies, one count of failure to transmit taxes, a felony, and one count of failure to maintain workers’ compensation insurance, a misdemeanor. The remaining counts were dismissed with a waiver allowing the Court to consider them for purposes of sentencing and restitution.

Jenkins was ordered to serve 364 days in custody concurrent with a two-year prison term he will be serving in an unrelated case.

He was also ordered to pay restitution of $55,761 to Care West Insurance for unpaid workers’ compensation premiums, $500 for unpaid wages, $332 to three former employees for out-of-pocket costs due to injuries on the job, and $7,576 for unpaid tax withholdings.

He has already paid $127,944.78 in restitution for unpaid wages to 31 former employees, and $31,000.00 in unpaid taxes to the Employment Development Department.

Cal Chamber of Commerce Updates 2022 Legislative Job Killer List

Each year the California Chamber of Commerce releases a list of job killer bills to identify legislation that it says will decimate economic and job growth in California. The CalChamber tracks the bills throughout the rest of the legislative session and works to educate legislators about the serious consequences these bills will have on the state.

Following the April 29 deadline for legislation to be referred to fiscal committees, several bills identified by the California Chamber of Commerce as job killers will not be advancing this year. The 2022 list now consists of 12 bills, including two carry-over proposals from 2021. CalChamber monitors changes in legislation and will add bills to the list as appropriate.

The good news is that the proposal for a 32 hour work week in California seems to no longer be a problem.  AB 2932 (Low; D-Campbell) significantly increases labor costs by imposing an overtime pay requirement after 32 hours and other requirements that are impossible to comply with, exposing employers to litigation under the Private Attorneys General Act (PAGA). In Assembly Labor and Employment Committee. Failed deadline to move from policy committee to fiscal committee, April 29, 2022.

One bill remains on the Workers’ Compensation section of the list. SB 213 (Cortese; D-San Jose) significantly increases workers’ compensation costs for public and private hospitals by presuming certain diseases and injuries are caused by the workplace and establishes an extremely concerning precedent for expanding presumptions into the private sector. 2021 carry-over bill.

And there are several employment law related proposals that remain on the Job Killer list.

AB 2095 (Kalra; D-San Jose) places new onerous administrative burdens on employers by requiring annual reporting of wage and hour data and employee benefits on an employer’s entire United States workforce that will unfairly criticize employers for lawful conduct by publishing that data on the Labor and Workforce Development Agency’s website and using such data to rank employers and deny them state opportunities, and will subject employers to frivolous litigation and settlement demands.

AB 2182 (Wicks; D-Oakland) imposes new burdens on employers to accommodate any employee with family responsibilities, which will essentially include a new, uncapped protected leave for employees to request time off and exposes employers to costly litigation under the Fair Employment and Housing Act by asserting that any adverse employment action was in relation to the employee’s family responsibilities, rather than a violation of employment policies.

AB 2188 (Quirk; D-Hayward) risks workplace safety by promoting marijuana use to a protected class under California’s discrimination law, on par with national origin or religion. Also effectively prohibits pre-employment drug testing, harming employers’ ability to keep their workplace safe and drug free. In addition, would prohibit use of traditional marijuana tests, such as urine and hair testing, and compel employers to utilize saliva-based testing.

SB 1044 (Durazo; D-Los Angeles) allows employees to leave work or refuse to show up to work if employee subjectively feels unsafe regardless of existing health and safety standards or whether employer has provided health and safety protections and subjects employers to costly Private Attorneys General Act (PAGA) lawsuits if they dispute the employee’s decision or need to have another employee take over any job duties.

AB 2289/ ACA 8 (Lee; D-San Jose) seeks to impose a massive tax increase upon all forms of personal property or wealth despite California already having the highest income tax in the country. This tax increase will drive high-income earners and job creators out of the State as well as the revenue they contribute to the General Fund.

Stanford Professor Testifies Against Walgreens in S.F. Opioid Trial

San Francisco’s opioid lawsuit against Walgreens and a number of pharmaceutical companies commenced its trial, late last month. The suit was filed in 2018 against a panoply of defendants, but many of them have since been dismissed.thanks to settlements. But some parties remain, including Walgreens, Actavis, Teva Pharmaceuticals and Endo Pharmaceuticals.

The trial marks another instance of a governmental entity accusing drugmakers and sellers of creating a “public nuisance,” an attempt to collect damages over an addiction epidemic that persists to this day. This past November, an Orange County Superior Court judge ruled in favor of four pharmaceuticals, including Teva, in a suit brought by four cities and counties. That same month, the Oklahoma Supreme Court overturned a $465 million ruling against Johnson & Johnson.

A jury trial in Florida ended midtrial, when Walgreens agreed to settle claims brought by the Sunshine State and its cities and counties for $683 million. Florida has received more than $3 billion from opioid litigation settlements, some from Teva and Allergan.

According to the report by Courthouse News, the San Francisco opioid trial picked up Monday May 9, after a one-week hiatus with the expert testimony of Dr. Anna Lembke, who said Walgreens and three other defendants in the civil suit helped spread misinformation that led to the opioid crisis that took nearly half a million lives. Lembke, is a Stanford University professor who teaches, conducts research and treats patients and the author ofDrug Dealer, MD” and “Dopamine Nation.”

The defendants in this case used misinformation to target doctors,” Lembke testified. “Walgreens actively collaborated with Purdue to educate their pharmacists on the use of treating pain with opioids.”

She added: “Walgreens strategized with Purdue about how to get these messages out there.

After a 45-minute presentation, Lembke faced cross-examination by lawyers for Teva and Allergan who attempted to get Lembke to admit their clients played minor roles in the opioid crisis and that any misinformation they disseminated – for example, that addiction rarely resulted from opioid prescriptions – was intended for “internal use” only.

Lembke pushed back, saying many of the internal documents were used to train sales representatives who visited doctors to convince them of both the safety of opioids and the necessity of treating pain seriously. “This massive misinformation campaign stripped doctors of the true appreciation of the danger of opioid use,” Lembke said.

Teva attorney Wendy Feinstein in her cross-examination, pushed the idea that the FDA and DEA shared responsibility for the oversupply and overprescription of opioids. The FDA, she noted, approved Oxycontin and other powerful narcotics for the treatment of pain, while the DEA sets production quotas – limits on how many opiates can be produced by various manufacturers.

There is lots of blame to go around,” Lembke said.

State governments, too, played a role in the paradigm shift. California passed a number of laws, including the Intractable Pain Act in 1990 and the Pain Patients Bill of Rights in 1997, the latter of which required “doctors to advise patients who suffer from -‘severe, chronic (and) intractable’ pain that powerful narcotics are legally available that could grant them relief.”

Later, Allergan attorney Hariklia Karis asked Lembke if she thought that doctors were more influenced by sales representatives than they were by the FDA-approved drug labels, which state warnings about the various dangers of taking a drug.

“Yes,” Lembke said, adding doctors don’t always have time to keep up with the latest research and are “much more influenced by peers and sales reps.”

Lembke’s testimony will resume Wednesday.

Correctional Officer S&W Award Calc Includes Enhanced IDL Benefit

Michael Ayala sustained an injury in 2002 while employed as a correctional officer by the Department of Corrections & Rehabilitation/Lancaster State Prison as a result of an attack on prison staff by the inmates. The parties entered into Stipulations with Request for Award that the injury caused 85% permanent disability. The Award was approved on July 31, 2012.

Ayala filed a petition alleging that the injury occurred as a result of serious and willful misconduct by defendant per Labor Code section 4553. The WCJ found in a 2018 Finding of Fact that the employer did not engage in serious and willful misconduct.

However reconsideration was granted in April 2020 and the Appeals Board issued a decision finding that he sustained an injury as a result of serious and willful misconduct by defendant. The decision included an award for a 50% increase in compensation.

The case proceeded to trial again on July 29, 2021 to calculate the 50% increase in benefits. One of the issues was to determine if the computation of the S & W award applies to all the benefits Ayala received, including or the Enhanced Industrial Disability Leave. He was paid enhanced IDL at the rate of his full salary for 845 days, valued at $155,000, 50% of which would be $77,500.

WCJ found that the Appeals Board lacks jurisdiction to award industrial disability leave (IDL) benefits, However, reconsideration was again granted, and the WCAB panel issued another new decision finding that Ayala was entitled to a 50% increase in compensation per section 4553 to be calculated based on the enhanced IDL he received, in the WCAB panel decision of Ayala v Department of Corrections ADJ1360597 (April 2022).

The panel stated that “there is no dispute that the Appeals Board does not have jurisdiction to award IDL, enhanced or otherwise.” However “the Appeals Board unquestionably has jurisdiction to issue and calculate applicant’s serious and willful award that he is entitled to under section 4553.”

Government Code section 19871 provides for state employees to receive IDL (full pay less withholding for taxes and certain deductions/contributions) for 52 weeks when they are temporarily disabled due to an industrial injury. Certain employees receive “enhanced” IDL pursuant to Government Code section 19871.2

Section 4553 provides that the “amount of compensation otherwise recoverable shall be increased one-half.” Ayala contends that “compensation otherwise recoverable” includes enhanced IDL. He argues that the language “otherwise recoverable” extends to compensation beyond what is contained in the definition of compensation in Labor Code section 3207.  He further argues that Government Code section 19870 provides that IDL “means temporary disability as defined in” division 4 of the Labor Code, which is why IDL payments have been considered in calculating aggregate disability payments under section 4656 per Brooks v. Workers’ Comp. Appeals Bd. (2008) 161 Cal.App.4th 1522 [73 Cal.Comp.Cases 447].

The WCAB panel essentially agreed with these arguments. And it went on to discuss the purpose of 4553 since the fundamental rule of statutory construction is that a court should ascertain the intent of the Legislature so as to effectuate the purpose of the law.

In Ferguson v. Workers’ Comp. Appeals Bd. (1995) 33 Cal.App.4th 1613, 1621 [60 Cal.Comp.Cases 275], the Court of Appeal held “that an award for increased compensation due to the serious and willful misconduct of an employer under section 4553 must be calculated with reference to ‘every benefit or payment conferred by Division 4 upon an injured employee’ as broadly defined in section 3207.” The Court in Ferguson acknowledged that section 4553 is not quite consistent with the no-fault principle applicable to the workers’ compensation system.  

Applying the interpretation principles, in this case the panel concluded that “the purpose of an award under section 4553 is to more fully compensate the employee for an injury caused by the employer’s serious and willful misconduct. This purpose is best served by interpreting ‘compensation otherwise recoverable’ as including applicant’s enhanced IDL payments, which provides for a greater amount of compensation than calculating the section 4553 award based on his temporary disability rate.”

Cal/OSHA Approves Updated COVID-19 Temporary Standards

Cal/OSHA posted fact sheets and updated its FAQs on COVID-19 Prevention Emergency Temporary Standards (ETS) to reflect revisions adopted by the Occupational Safety and Health Standards Board on April 21, 2022.

The ETS revisions incorporate updated guidance from the California Department of Public Health (CDPH) and make the ETS more flexible if changes are made to CDPH guidance in the future.

The updated ETS standards are in effect now through December 31, 2022. They apply to most workers in California not covered by the Aerosol Transmissible Diseases Standard.

The fact sheets posted include:

– – What Employers Need to Know About the April 21, 2022 Standards
– – COVID-19 Isolation and Quarantine – What Employers and Workers Need to Know (Updated May 7, 2022)
– – Revisions to the COVID-19 Prevention Emergency Temporary Standards Updated May 7, 2022 – FAQs

Cal/OSHA helps protect workers from health and safety hazards on the job in almost every workplace in California. Employers who have questions or need assistance with workplace safety and health programs, including assistance with developing a COVID-19 prevention program at their worksite, can call Cal/OSHA’s Consultation Services Branch at 800-963-9424.

Workers who have questions about COVID-19 hazards at work can call 833-579-0927 to speak with a Cal/OSHA representative during normal business hours. Complaints about workplace safety and health hazards can be filed confidentially with Cal/OSHA district offices.

Employers with Questions on Requirements May Contact: InfoCons@dir.ca.gov or call your local Cal/OSHA Consultation Office.

Ruling in Kaiser Fraud Case Illustrates Sophisticated Upcoding Strategies

The United States has intervened in six complaints pending in Northern California federal court, alleging that members of the Kaiser Permanente consortium violated the False Claims Act by submitting inaccurate diagnosis codes for its Medicare Advantage Plan enrollees in order to receive higher reimbursements. The Kaiser Permanente consortium members are headquartered in Oakland, California.

The six lawsuits were filed under the qui tam, or whistleblower, provisions of the False Claims Act, which permit private parties to sue on behalf of the government and to receive a share of any recovery. The Act also permits the government to intervene in such lawsuits, as it has done here.

Ronda Osinek was the first-filed case and was followed by five other cases: Taylor, Arefi, Stein, Bryant, and Bicocca.The cases were consolidated in June 2021.

The Defendants’ filed a motion to dismiss based on the first-to-file bar in the False Claims Act . The Act provides that “When a person brings an action under this subsection, no person other than the Government may intervene or bring a related action based on the facts underlying the pending action.”

The court therefore was required to compare the Osinek Complaint with the complaints in the other cases to determine whether the cases are related, and thus the plaintiff who was the first-to-file only is allowed to proceed. The federal judge in a May 5 46 page ruling, allowed some claims but the majority of the claims were denied.

In the discussion leading up to the ruling, the opinion provides an excellent summary, if not a full treatise, on how sophisticated such efforts at “upcoding” and other Medicare billing strategies have become.

Adjustments are made to the payments to Medicare Advantage Plans based on demographic information and the diagnoses of each plan beneficiary. The adjustments are commonly referred to as “risk scores.” A beneficiary with more severe diagnoses will have a higher risk score, and CMS will make a larger risk-adjusted payment to the MA Plan for that beneficiary.

How can this be the subject of a whistleblower claim? Osinek alleged that starting around 2007, Kaiser Permanente began a “scheme to upcode diagnoses to ensure Medicare payments for reimbursable, high-value conditions.” This was done was by use of data mining for high value cases, and then determining the diagnoses its doctors would need to make to support the Medicare reimbursement.

She then alleges that there is “an escalation process for physicians who do not agree with the data mining prompts”; “[p]hysicians will have to meet one-on-one with Data Quality Trainers if they refused to make diagnoses changes that are presented by data mining”; “physicians have personal report cards based on how they perform in certain areas [including response to refreshing and data mining prompts], which are tied to their compensation”; and there are “mandatory meetings called ‘coding parties,’ where physicians are gathered in a single room with computers and asked to review past progress notes for addenda related to revised medical diagnoses.”

Another strategy was “refreshing” with Osinek alleging that “Kaiser tracks and rewards physicians based on the percentage of chronic conditions they are able to capture and refresh.” If a patient has a chronic condition, then that condition must be rediagnosed each year ” i.e., refreshed. She alleged the doctor would be told to include the chronic condition as a diagnosis for a visit even if that condition was not at issue in the patient visit.
And Kaiser allegedly provided guidance or policies that supported upcoding. For example, “Kaiser told its physicians to diagnose chronic kidney disease instead of the lower value nephritis or nephropathy.”

Kaiser allegedly had its doctors use addenda to retroactively diagnose – e.g., long after a patient visit, for a condition for which the patient was not treated at the time of the face-to-face visit, based on tests run after the face-to-face visit, to change a diagnosis to a higher value and more complicated form of disease, without proper support/documentation, and/or using boilerplate language.

The 46 page Opinion, then compares and contrasts the allegations in the Osinek complaint, with those in the other cases, which then exposes nuances and embellishments. For example, Dr. Taylor in his complaint claims that his differs from the Osinek Complaint because he has made allegations about Kaiser’s Natural Language Processing (“NLP”) software. “All face-to-face visits to a physician or hospital . . . are run through the NLP software to identify new diagnoses that might be appropriate to use for submission of additional risk adjustment claims.” And goes on to argue that “different frauds were implicated in each case.”

The Court concluded that the nature of wrongdoing claimed by Dr. Taylor here involves different “material elements” from Osinek.

“The Taylor case is not dismissed in its entirety but only in part. Taylor differs materially from Osinek in three ways: (1) Taylor points to a nationwide or corporate-wide problem whereas Osinek is local or regional (i.e., California-centric) in nature; (2) Taylor has identified a fraud related to external providers rather than high-value conditions; and (3) Taylor asserts a problem with Kaiser failing to evaluate the True Positives results yielded by the NLP program.”

A similar process was used to evaluate the other plaintiffs, with some being dismissed in their entirety.